跳至主要内容
临床试验/JPRN-UMIN000003181
JPRN-UMIN000003181已完成未知

Comparison of Helicobacter pylori Eradication plus Rebamipide combination therapy with proton pump inhibitor(PPI) alone in the treatment of endoscopic submucosal dissection(ESD) induced ulcers in H.pylori positive eary gastric cancer: Prospective Randomized Pilot Syudy - Helicobacter pylori Eradication plus Rebamipide promotes gastric ulcer healing after Endoscopic Submucosal Dissection(ESD): Prospective Randomized Pilot Syudy

Osaka Medical College0 个研究点目标入组 120 人开始时间: 2010年2月14日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 75years-old(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1)The patient with past H.pylori eradication treatment 2)The patient who coexists for active gastroduodenal ulcer 3)Upper gastrointestinal tract ablative operation and the patient with medical history of vagotomy 4)The patient who does not become a subject of medical treatment for perforation/pyloric stenosis, a massive bleeding case. 5)The patient who could not interrupt the antiplatelet agent or anticoagulant temporarily for ESD therapy. 6)The patient with medical history of shock by amoxicillin. 7)The patient with glandular infection. 8)The patient with anaphylactic medical history for penicillin antimicrobial agent, clarithromycin, a proton pump inhibitor and rebamipide. 9)The patient who is administrated drug considered to be contraindication of clarithromycin(terfenadine, cisapride, pimoside). 10)The patient with grave complication(respiratory tract disease, kidney disease, treatment by use of insulin or diabetes mellitus inadequate control) and a hindrance for examination enforcement. 11)Inadequate to entry judged by investigators.

研究者

相似试验

Comparison of Helicobacter pylori Eradication plus... | 临床试验